



#8

Express Mail No.: EV 335 855 710 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Sakata et al.

Confirmation No.: 8859

Application No.: 10/071,390

Group Art Unit: 1626

Filed: February 7, 2002

Examiner: R. Gerstl

For: ISOTHIAZOLOANTHRONRES,  
ISOXAZOLOANTHRONES,  
ISOINDOLANTHRONES AND  
DERIVATIVES THEREOF AS  
JNK INHIBITORS AND  
COMPOSITIONS AND  
METHODS RELATED THERETO

Attorney Docket No.: 10624-053-999

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 and 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **CP-CS** which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." A copy of references **CP-CS** is enclosed.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review each of the references identified on the attached Form PTO-1449, and that the references be made of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. § 1.97(b)(2), since this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, no fee is believed to be due. However, should the Patent and Trademark Office determine that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this document is enclosed for accounting purposes.

Respectfully submitted,

*Anthony M. Insogna, N.Y. No. 35,203*  
*By: Matthew E. Long, N.Y. No. 36,343*

Date June 25, 2003

35,203

Anthony M. Insogna


(Reg. No.)

**PENNIE & EDMONDS LLP**

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

 <p><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p>	ATTY DOCKET NO. 10624-053-999	APPLICATION NO 10/071,390
	APPLICANT Sakata et al.	
	FILING DATE February 7, 2002	GROUP 1626

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
CP	WO 99/53927	October 29, 1999	PCT				
CQ	WO 02/085396	October 31, 2002	PCT				

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

CR	Spiegelman et al., "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> 268:6823-6826 (1993).
CS	Hirosumi et al., "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> 420:333-336 (2002).

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	